

China Paper Industry Thermometer

Dec data: overall weaker m/m data points to seasonal slowdown

Industry Overview

December data points to seasonal slowdown

December was another weaker month sequentially, indicating the paper and board market in China may have already peaked. On a consolidated basis output was up 0.8% y/y, but down 3.5% m/m, as output dropped m/m for uncoated paper, ivory board and tissue but rose for coated woodfree and duplex. Meanwhile, aggregate inventories rose 2.7% m/m, led by inventory increases in all grades, except tissue. Tissue and coated paper prices dropped in December by 2.5% and 1.8% m/m respectively and uncoated woodfree paper and ivory board saw inventory increases m/m despite the output drop. On the positive side, paper export y/y growth remained at double digit in November and has been a key factor in the Chinese paper & board market pickup. We expect hardwood prices to remain capped in the near term around \$650-660/t. While we do see signs that the pulp market has peaked, we believe any potential price correction ahead should be shallow and short-lived given prices remain reasonably close to cost support at \$550/t.

Tissue: output down m/m and prices still pressured

Tissue operating rates in China dropped 770bp m/m in December to 48.6%, or down 520bp y/y. Total tissue output fell 13.4% m/m and 10.4% y/y to 774Kt in Dec, while enterprise tissue inventories dropped 1.3% m/m but was up 3.2% y/y to 558Kt. Tissue prices dropped 2.5% through December to RMB 6,400/t, down 18.4% throughout 2023.

Coated paper: output up m/m yet inventories climb

Coated paper operating rates rose 150bp m/m in Dec to 66.9%, up 20bp y/y. Coated paper output was up 4% m/m and 0.3% y/y to 408Kt in Dec. Inventories rose 2.1% m/m but was down 28.3% y/y to 392Kt, now at 24 days of supply, up one day m/m. Meantime, coated paper prices were down 1.8% m/m in December to RMB 5,930/t, now up 6.1% through 2023.

UWF paper: output down and inventories up m/m

Uncoated woodfree paper operating rates dropped 4.0ppt m/m in Dec to 66%, down 10bp y/y. Meantime, total uncoated paper production fell 2.2% m/m but was up 9.6% y/y to 848Kt in Dec, while inventories rose 3.5% m/m to 490Kt (down 22.8% y/y).

Ivory board: output down, inventories up m/m

lvory board operating rates were down 460bp m/m in December to 66.2%, above Dec-22's 65.4%. Total ivory board output dropped 3.3% m/m but was up 12.5% y/y to 977Kt in December, while enterprise inventories rose 7.9% m/m to 497Kt (down 25.3% y/y).

Duplex board: output up 4.5% m/m

Duplex board operating rates were up 160bp m/m but down 830bp y/y in December to 58%. Total duplex board output rose 4.5% m/m but dropped 9.8% y/y to 598Kt in Dec, while enterprise inventory rose 2.1% m/m to 591Kt (down 19.5% y/y).

03 January 2024

Equity Latin America Pulp & Paper

Caio Ribeiro Research Analyst BofAS +1 646 855 4051 caio.ribeiro@bofa.com

Leonardo Neratika >> Research Analyst Merrill Lynch (Brazil) +55 11 2188 4200 leonardo.neratika@bofa.com

Guilherme Rosito >> Research Analyst Merrill Lynch (Brazil) +55 11 2188 4363 guilherme.rosito@bofa.com

George L. Staphos Research Analyst BofAS +1 646 855 4495 george.l.staphos@bofa.com

P&B = paper and board

P&W = Printing and writing

HW = hardwood

UWF= Uncoated woodfree

Refer to "Other Important Disclosures" for information on certain BofA Securities entities that take responsibility for the information herein in particular jurisdictions.

BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Refer to important disclosures on page 16 to 17.

Timestamp: 03 January 2024 05:52PM EST

>> Employed by a non-US affiliate of BofAS and is not registered/qualified as a research analyst under the FINRA rules.

Tissue

Exhibit 1: Summary of China tissue statistics (Kt) and operating rates (%)

Output dropped 13.4% m/m to 774Kt, while inventories fell 1.3% m/m to 558Kt

	Dec-23	Nov-23	m/m (%)	m/m	Dec-22	y/y (%)	y/y	ytd
Operating rate (%)	48.6%	56.3%	-13.7%	-7.7	53.8%	-9.7%	-5.2	15.1%
Output (Kt)	774	894	-13.4%	-120	864	-10.4%	-90	17.9%
Import (Kt)	n.a.	4	n.a.	n.a.	2	n.a.	n.a.	n.a.
Export (Kt)	n.a.	30	n.a.	n.a.	16	n.a.	n.a.	n.a.
Consumption (Kt)	n.a.	841	n.a.	n.a.	847	n.a.	n.a.	n.a.
Enterprise inventory (Kt)	558	565	-1.3%	-7	540	3.2%	17	-1.1%

Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 2: Tissue - operating rates in China (%)

Tissue operating rates dropped to 48.6% in December




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 3: Tissue - operating rates in China (%)

Dec 2023 tissue op. rate was below the past four years average




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 4: Tissue - production volume in China (Kt)

Tissue output dropped 13.7% m/m and 9.7% y/y...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 5: Tissue – production volume in China (Kt)

... now below the past four years range for the first time this year




Source: BofA Global Research, SCI



Exhibit 6: Tissue – enterprise inventories in China (Kt)

Enterprise inventory reached 558Kt in Dec, down 1.3% m/m




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 8: Tissue - total domestic consumption in China (Kt)

Domestic consumption volume was at 841Kt in November...




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 7: Tissue - enterprise inventories in China (Kt)

Tissue inventories are slightly above the upper end of the past 4-years range




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 9: Tissue - total domestic consumption in China (Kt)

...slightly below its last four years average




Source: BofA Global Research, SCI, China NBS



Exhibit 10: Tissue - export volumes in China (Kt)


Export volume was at 30Kt in November



BofA GLOBAL RESEARCH

Exhibit 12: Tissue – import volumes in China (Kt)

Tissue import volumes were at 4.4Kt in November...



Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 11: Tissue - export volumes in China (Kt)

Tissue exports were above the past four years range in November




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 13: Tissue – import volumes in China (Kt)

... at the upper end of its past four years range



Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 14: Tissue – average prices in China (RMB/t)

Average tissue prices currently at RMB 6,400/t



Source: BofA Global Research, SCI



Coated paper

Exhibit 15: Summary of China coated paper statistics (Kt) and operating rates (%)

Output rose 4.0% m/m to 408Kt, while inventories rose 2.1% m/m to 392Kt or 24 days of supply

	Dec-23	Nov-23	m/m (%)	m/m	Dec-22	y/y (%)	y/y	ytd
Capacity (Kt)	609	590	3.3%	20	609	0.0%	0	1.0%
Shandong	260	252	3.3%	8	260	0.0%	0	0.2%
Jiangsu	256	248	3.3%	8	256	0.0%	0	-0.2%
Hainan	93	90	3.3%	3	93	0.0%	0	6.7%
Operating rate (%)	66.9%	65.4%	2.4%	1.5	66.7%	0.3%	0.2	6.4%
Output (Kt)	408	392	4.0%	16	406	0.3%	1	6.5%
Import (Kt)	n.a.	22	n.a.	n.a.	16	n.a.	n.a.	-15.1%
Export (Kt)	n.a.	151	n.a.	n.a.	123	n.a.	n.a.	-11.5%
Consumption (Kt)	n.a.	263	n.a.	n.a.	300	n.a.	n.a.	1.6%
Inventory								
Volume (Kt)	392	384	2.1%	8	547	-28.3%	-155	-3.8%
Days	24	23	1.8%	0	33	-28.3%	-9	-3.8%

Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 16: Coated paper - operating rate in China (%)

Operating rates increased to 66.9% in December...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 18: Coated paper - output volume in China (Kt)

Coated paper output rose 4.0% m/m and 0.3% y/y...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 17: Coated paper - operating rate in China (%)

... now below its past four years average




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 19: Coated paper - output volume in China (Kt)

... but remained below its past four years average




Source: BofA Global Research, SCI



Exhibit 20: Coated paper - inventory in China

Coated paper inventory reached 392Kt in December...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 22: Coated paper - consumption in China (Kt)

Coated paper consumption volume was at 263Kt in November...




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 24: Coated paper – export volume in China (Kt)

Coated paper exports were at 151Kt in November, flattish m/m...




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 21: Coated paper - inventory in China

Now slightly below its past four years average




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 23: Coated paper - consumption in China (Kt)

... below the bottom end of its last four years range




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 25: Coated paper – export volume in China (Kt)

... and at the upper end of its last four years range



Source: BofA Global Research, SCI, China NBS



Exhibit 26: Coated paper - import volume in China (Kt)

Coated paper imports were at 22Kt in November, stable m/m...




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 28: Coated paper - average price (RBM/t)

Average coated paper prices fell 1.8% m/m in early Jan to RMB 5,930/t




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 27: Coated paper - import volume in China (Kt)

... and close to its last four years average



Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 29: Coated paper - gross profit rate (%)

Coated paper gross profit rate fell slightly m/m to 7.66% by early January




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 30: Coated paper - capacity in China (Kt)

Capacity was up m/m to 609Kt/month, with most of it coming from Shandong and Jiangsu



Source: BofA Global Research, SCI



Uncoated woodfree paper

Exhibit 31: Summary of China uncoated woodfree paper statistics (Kt) and op. rates (%)

Output fell 2.2% m/m to 848Kt, while inventories rose 3.5% m/m to 490Kt


	Dec-23	Nov-23	m/m (%)	m/m	Dec-22	y/y (%)	y/y	ytd
Operating rate (%)	66.0%	70.0%	-5.7%	-4.0	66.1%	-0.2%	-0.1	7.8%
Output (Kt)	848	867	-2.2%	-19	774	9.6%	74	16.5%
Import (Kt)	n.a.	18	n.a.	n.a.	14	n.a.	n.a.	n.a.
Export (Kt)	n.a.	98	n.a.	n.a.	99	n.a.	n.a.	n.a.
Consumption (Kt)	n.a.	787	n.a.	n.a.	689	n.a.	n.a.	n.a.
Enterprise inventory (Kt)	490	474	3.5%	16	635	-22.8%	-145	-16.1%

Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 32: UWF - operating rate in China (%)

Uncoated woodfree paper operating rates reached 76% in December...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 34: UWF - output volume in China (Kt)


Uncoated woodfree paper output dropped 2.2% m/m...



BofA GLOBAL RESEARCH

Exhibit 33: UWF - operating rate in China (%)

... now below its past four years average




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 35: UWF - output volume in China (Kt)

... but remained well above its past four years range in December




Source: BofA Global Research, SCI



Exhibit 36: UWF - inventory in China (Kt)

Uncoated woodfree paper inventory reached 490Kt in Dec...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 38: UWF - consumption in China (Kt)

Uncoated woodfree paper consumption was at 787Kt in November...




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 37: UWF - inventory in China (Kt)

... and remained at the bottom end of its past four years range




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 39: UWF - consumption in China (Kt)


... up m/m and at the upper end of its past four years range



Source: BofA Global Research, SCI, China NBS

Exhibit 40: UWF - export volume in China (Kt)

Uncoated woodfree paper exports were at 98Kt in November...



Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 42: UWF - import volume in China (Kt)

Uncoated woodfree paper imports were at 18Kt in November...




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 41: UWF - export volume in China (Kt)

... above the upper end of its past four years range



Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 43: UWF - import volume in China (Kt)

... close to the bottom of its past four years range



Source: BofA Global Research, SCI, China NBS

Ivory board

Exhibit 44: Summary of China ivory board statistics (Kt) and operating rates (%)

Output fell 3.3% m/m to 977Kt, while inventories rose 7.9% m/m to 497Kt

	Dec-23	Nov-23	m/m (%)	m/m	Dec-22	y/y (%)	y/y	ytd
Operating rate (%)	66.2%	70.8%	-6.5%	-4.6	65.4%	1.2%	0.8	-10.1%
Output (Kt)	977	1,011	-3.3%	-34	868	12.5%	109	2.5%
Import (Kt)	n.a.	43	n.a.	n.a.	51	n.a.	n.a.	-4.8%
Export (Kt)	n.a.	341	n.a.	n.a.	239	n.a.	n.a.	-8.8%
Consumption (Kt)	n.a.	867	n.a.	n.a.	747	n.a.	n.a.	1.1%
Enterprise inventory (Kt)	497	460	7.9%	37	665	-25.3%	-168	-2.6%

Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 45: Ivory board - operating rate in China (%)


Ivory board operating rates were down to 66.2% in December...



Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 46: Ivory board - operating rate in China (%) ... now at the bottom end of its past four years range




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 47: Ivory board - output volume in China (Kt)

Ivory board output dropped 3.3% m/m but rose 12.5% y/y to 977Kt...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 48: Ivory board - output volume in China (Kt)

... well above the upper end of its past four years range




Source: BofA Global Research, SCI



Exhibit 49: Ivory board - enterprise inventory in China (Kt)

Ivory board inventory rose m/m to 497Kt in December...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 51: Ivory board - consumption in China (Kt)

Ivory board consumption was at $86 Ktin\ November...$




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 50: Ivory board - enterprise inventory in China (Kt)

... but remained well below its past four years average



Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 52: Ivory board - consumption in China (Kt)

... above its past four years range



Source: BofA Global Research, SCI, China NBS



Duplex board

Exhibit 53: Summary of China Duplex board statistics (Kt) and operating rates (%)

Output rose 4.5% m/m to 598Kt, while inventories rose 2.1% m/m to 591Kt

	Dec-23	Nov-23	m/m (%)	m/m	Dec-22	y/y (%)	y/y	ytd
Operating rate (%)	58.0%	56.4%	2.9%	1.6	66.3%	-12.5%	-8.3	-1.3%
Output (Kt)	598	573	4.5%	26	664	-9.8%	-65	-4.2%
Import (Kt)	n.a.	43	n.a.	n.a.	51	n.a.	n.a.	-4.8%
Export (Kt)	n.a.	341	n.a.	n.a.	239	n.a.	n.a.	-8.8%
Consumption (Kt)	n.a.	546	n.a.	n.a.	657	n.a.	n.a.	-7.5%
Enterprise inventory (Kt)	591	579	2.1%	12	734	-19.5%	-143	-6.5%

Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 54: Duplex - operating rate in China (%)

Duplex board operating rate reached 58% in December...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 56: Duplex - output in China (Kt)

Duplex board output rose 4.5% m/m but dropped 9.8% y/y to 598Kt ...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 55: Duplex - operating rate in China (%)

... below the low-end of its past four years range




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 57: Duplex - output in China (Kt)

... in December, below its past four years range




Source: BofA Global Research, SCI



Exhibit 58: Duplex - enterprise inventory in China (Kt)

Duplex board inventory reached 591Kt in December...




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 60: Duplex – consumption in China (Kt)

Duplex board consumption was at 546Ktin November, up 6.1% y/y...




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 59: Duplex - enterprise inventory in China (Kt)

... above its past four years average




Source: BofA Global Research, SCI

BofA GLOBAL RESEARCH

Exhibit 61: Duplex – consumption in China (Kt)


... and close to the bottom end of its past four years range



Source: BofA Global Research, SCI, China NBS

Exhibit 62: Duplex & Ivory Board - export volume in China (Kt)


Duplex & ivory board combined exports were at 341Kt, up 24.5% y/y...



BofA GLOBAL RESEARCH

Exhibit 64: Duplex & Ivory Board – import volume in China (Kt)

Duplex & ivory board combined imports were at 43Kt, down 33% y/y...




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 63: Duplex & Ivory Board - export volume in China (Kt)

... and above the upper end of the past four years range in November




Source: BofA Global Research, SCI, China NBS

BofA GLOBAL RESEARCH

Exhibit 65: Duplex & Ivory Board - import volume in China (Kt)

... and close to its past four years range in November



Source: BofA Global Research, SCI, China NBS



Disclosures

Important Disclosures

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.

Other Important Disclosures

From time to time research analysts conduct site visits of covered issuers. BofA Global Research policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments. Refer to BofA Global Research policies relating to conflicts of interest.

"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.

Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at www.bofaml.com/BofASEdisclaimer, BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI, BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Canadian Investment Regulatory Organization; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information in Germany and is regulated by BaFin, the ECB and the CBI. BofA Securities entities, i

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial



instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

Copyright and General Information:

Copyright 2024 Bank of America Corporation. All rights reserved. iQdatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities. Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public inform

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.

